Rituximab, a monoclonal antibody targeting CD20 on B lymphocytes, and long-term anti-BLyS/BAFF therapy, belimumab, revealed promising results in neuroimmune abnormalities in pSS [142,163] (Table 1). Here, TNFSF13B is linked to peeling skin syndrome.